1. Home
  2. DFIN vs MIRM Comparison

DFIN vs MIRM Comparison

Compare DFIN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Donnelley Financial Solutions Inc.

DFIN

Donnelley Financial Solutions Inc.

HOLD

Current Price

$46.31

Market Cap

1.2B

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$78.82

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFIN
MIRM
Founded
1983
2018
Country
United States
United States
Employees
1800
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
4.2B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
DFIN
MIRM
Price
$46.31
$78.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
11
Target Price
$63.50
$92.45
AVG Volume (30 Days)
267.6K
813.7K
Earning Date
10-29-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.12
N/A
Revenue
$750,800,000.00
$471,794,000.00
Revenue This Year
N/A
$53.78
Revenue Next Year
$4.20
$19.91
P/E Ratio
$41.41
N/A
Revenue Growth
N/A
53.66
52 Week Low
$37.80
$36.88
52 Week High
$69.93
$82.58

Technical Indicators

Market Signals
Indicator
DFIN
MIRM
Relative Strength Index (RSI) 47.71 62.89
Support Level $45.72 $63.23
Resistance Level $46.57 $82.58
Average True Range (ATR) 1.17 3.74
MACD 0.12 1.62
Stochastic Oscillator 69.26 81.03

Price Performance

Historical Comparison
DFIN
MIRM

About DFIN Donnelley Financial Solutions Inc.

Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: